|Articles|June 16, 2020
Pratia and KFGN Join Forces
Advertisement
Pratia Inc has claimed 40% shares in KFGN, with an overall investment plan that assumes increased shareholding up to a clear majority position in the upcoming years. Dr. Ole Dammann will continue his leadership as CEO of KFGN. Additionally, as a Board Member of Pratia, he will support international growth of Site Network.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Approves GSK’s Exdensur for Severe Asthma Based on SWIFT Phase III Data
2
Unlocking Unstructured Health Data: Scaling eSource-Enabled Clinical Trials
3
ACT Brief: Rethinking Site Support in 2026, GSK’s New Severe Asthma Approval, and Priority Review Momentum in Multiple Myeloma
4
What Patients Want from Remote Trials: New Survey Data Reveals Preferences Around Usability, Trust, and Participation
5